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Aims. To measure blood and tissue concentrations of the H1-receptor antagonist, bepotastine besilate (BB). Methods. Participants
included 14 men and six women, whose age ranged from 13 to 76 years, with chronic rhinosinusitis, who underwent endoscopic
sinus surgery at our university hospital. Among them, 10 participants had allergic rhinitis (AR) (Group I), and others did not have
AR (Group II). Nasal mucosa and blood were collected 55 to 130 minutes after oral administration of BB 10mg. Concentrations
of the agent in the serum and nasal mucosa were measured by high-performance liquid chromatography. Results. Concentrations
of BB of the serum in Group I and II were 98 ± 32ng/mL and 112 ± 39ng/mL. Those of the nasal mucosa tissue in Groups I and
II were 101 ± 36ng/g and 132 ± 44ng/g. There was no signiﬁcant diﬀerence in the values of concentration of BB between the
serum and the nasal mucosa in either Group I or II (P = .757 and P = .2662, resp., Paired t-test). Conclusion. This preliminary
study is considered the ﬁrst report on the concentration of H1-receptor antagonists in nasal mucosa. The prompt absorption and
transition to the nasal mucosa of BB seems to have an eﬀect on allergic rhinitis.
Copyright © 2009 Kenji Takasaki et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
The H1-receptor antagonist, bepotastine besilate, was devel-
oped in Japan and is now widely used for allergic rhinitis in
Japan and Korea [1, 2]. Measurement of the concentrations
of the H1-receptor antagonist in nasal mucosa may provide
more direct information about the correlation between the
localconcentrationoftheagentandnasalhistamineblocking
action. However, to our knowledge, there has never been
a report measuring the concentrations of any H1-receptor
antagonist in nasal mucosa. The aim of this study is to
measure blood and tissue concentrations of bepotastine
besilate in patients with chronic rhinosinusitis (CRS).
2.SubjectsandMethods
Participants included 14 men and six women, whose age
ranged from 13 to 76 years (mean age of 48), with CRS,
who underwent endoscopic sinus surgery at our univer-
sity hospital. Their CRS was diagnosed by their clinical
symptoms and signs (nasal discharge, nasal obstruction, and
so on). Computed tomography demonstrated soft tissue
density in their paranasal cavities. With the exception of
CRS, the participants were healthy. None had a history
of renal, liver, or blood disease, nor were they taking any
other medications that might have aﬀected metabolism
and distribution of bepotastine besilate. Among them, 10
participants had allergic rhinitis (AR) (Group I), and others
did not have AR (Group II). AR in the participants of
Group I had been diagnosed as persistent allergic rhinitis
by their clinical symptoms, plus signs, and serum-speciﬁc
Immunoglobulin E (IgE) based on the ARIA’s deﬁnition [3]
(Table 1).
Nasal mucosa was collected from the anterior portion of
the inferior turbinate using forceps under general anesthesia
55 to 130 minutes after single-dose oral administration
of bepotastine besilate 10mg. There was no signiﬁcant
diﬀerence in the sampling times between the two groups
(t-test, P = .1178). The mean weight of the nasal mucosa
was approximately 24mg. Blood was collected at the same
time as the collection of the nasal mucosa. The blood was
immediately centrifuged to obtain the serum. The serum2 International Journal of Otolaryngology
Table 1: Characters of the participants and results of the concentration of BB in the serum and nasal mucosa.
Sampling time after Concentration Concentration
Case Age (years) Sex oral administration in the serum in the nasal mucosa Antigen
of BB (h:m) (ng/mL) (ng/g)
Group I
1 53 Male 1:10 155.98 111.05 Amb, Asp, Candida, Cha, Cry, Dp, HD
2 25 Female 1:30 132.34 108.3 Cha, Cry, Dp, HD
3 29 Male 1:35 67.98 47.79 Cha, Cry, Dp, HD
4 68 Male 1:40 98.14 76 Dp, HD
5 68 Male 1:40 74.62 79.57 Candida, Dp, HD
6 31 Male 1:45 49.35 97.3 Cha, Cry, Dp, HD
7 60 Male 1:50 86.85 99.2 Candida, Cha, Cry, Dp, HD
8 55 Male 2:00 109.27 108.6 HD
9 17 Female 2:00 83.5 98 Amb, Asp, Candida, Dp, HD
10 13 Male 2:10 119.41 186.1 Cry, Dp
Group II
11 38 Female 0:55 96.22 183.67 non
12 57 Male 1:00 71.38 66.7 non
13 55 Female 1:20 137.21 138.2 non
14 52 Male 1:20 121.58 141.5 non
15 46 Male 1:30 65.04 163.88 non
16 64 Female 1:30 107.48 187.01 non
17 52 Female 1:40 197.55 123.85 non
18 50 Male 1:40 85.14 57.86 non
19 76 Male 2:00 141.6 150.57 non
20 56 Male 2:00 95.47 108.7 non
Amb: Ambrosia elatior; Asp: Aspergillus; BB: Bepotastine Besilate; Cha: Chamaecyparis obtuse; Cry: Cryptomeria japonica; Dp: Dermatophagoides
pteronyssinus; HD: Housedust.
and nasal mucosa were promptly frozen and preserved at
−40
◦. Concentrations of the agent in the serum and tissue
were measured by high-performance liquid chromatography
using an API-4000 LC-MS-MS system (Applied Biosystems
Co., Ltd, California, USA). The sensitivity and reproducibil-
ity of the LC-MS-MS system were 98.0% and 98.9%,
respectively. Chromatographic separation was achieved on a
CapcellPakMGIIC18(2.0×150mm,3μm;Shiseido,Tokyo,
Japan), and the column temperature was maintained at 40
degrees. The lower limit of quantitation for serum and nasal
mucosa was 1ng/mL and 2ng/g, respectively.
To compare the concentration of bepotastine besilate
of the serum and nasal mucosa tissue in each group, we
statistically evaluated the data with a paired t-test. To
compare the concentration of bepotastine besilate in the
nasal mucosa tissue between the two groups, we used Mann-
Whitney’s U-test.
The protocol was approved by our hospital’s ethics
committee and informed consent was obtained from all the
participants.
3. Results
The concentration of bepotastine besilate of the serum in
Groups I and II ranged from 67.98 to 155.98ng/mL (a
mean and standard deviation: 98 ± 32) and from 65.04 to
197.55ng/mL(112±39)(Table 1).Thoseofthenasalmucosa
tissue in Groups I and II ranged from 47.79 to 186.1ng/g
(101±36)andfrom57.86to187.01ng/g(132±44)(Table 1).
There was no signiﬁcant diﬀerence in the values of
concentration of bepotastine besilate between the serum
and the nasal mucosa in either Group I or II (P = .757
and P = .2662, Paired t-test, Figures 1 and 2). There was
a tendency for the concentration of bepotastine besilate
in the nasal mucosa to be higher in Group II than in
Group I (P = .0696, Mann-Whitney’s U-test) (Figure 3).
These results may indicate swift absorption and transition of
bepotastine besilate from the gastrointestinal tract to blood
and from blood to tissue.
4. Discussion
P-glycoproteins, which aﬀect the tissue concentration of the
drugs, were reported to be expressed in the human nasal
mucosa [4]; hence we guess whether the tissue concentration
of the drug is the same as the serum concentration of
it or not. In fact, there were many reports on the tissue
concentration of antimicrobial and anticancer drugs in the
human nasal and paranasal region [5–7]. Histamine is an
important chemical mediator in allergic rhinitis and plays
an important role in eliciting the nasal symptoms of the
disorder [8]. H1-receptors are also known to exist on the
postcapillary venules in nasal mucosa to induce vasodilation,
to increase vascular permeability, and to stimulate sensoryInternational Journal of Otolaryngology 3
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Figure 1: The graph showed the result of the concentration of
bepotastine besilate in the serum and nasal mucosa of chronic
rhinosinusitis with allergic rhinitis and compares using a paired t-
test.
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Figure 2: The graphs demonstrated the result of the concentration
of bepotastine besilate in the serum and nasal mucosa of chronic
rhinosinusitis without allergic rhinitis and compares using a paired
t-test.
nerve endings in response to histamine [9]. There has been a
lot of literature reporting the concentration of H1-receptor
antagonists in the serum [1, 2, 10] and there was only
one report about it in human skin [11]. However, to our
knowledge, there has been no report actually measuring the
concentration of H1-receptor antagonists in nasal mucosa.
Therefore, this preliminary study is considered the ﬁrst
report of its kind.
It is known that the rise of the concentration of
bepotastine besilate in the serum after administration is
more rapid than the other H1-receptor antagonists and that
the t-max and half-lives (t1/2) in the serum were 1.2 hours
and 2.4 hours, respectively [2]. Therefore, we collected the
blood and nasal mucosa less than 2.4 hours after single-
dose oral administration of bepotastine besilate. There was
no signiﬁcant diﬀerence in the values of concentration
of bepotastine besilate between the serum and the nasal
mucosa. These results may indicate swift absorption and
transition of bepotastine besilate from the gastrointestinal
tract to blood and from blood to tissue. The results of the
present study indicating prompt absorption and transition
of bepotastine besilate seem to support the favorable eﬀects
of bepotastine besilate, which was reported to reveal a faster
clinical eﬀect of bepotastine besilate [12].
In the present study, we chose the CRS patients because
biopsy specimens could easily be taken. We feared that the
pathophysiologic changes accompanying CRS would not
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Figure 3:Theboxplotgraphshowedtheresultoftheconcentration
of bepotastine besilate in the nasal mucosa of chronic rhinosinusitis
with and without allergic rhinitis and compares using Mann-
Whitney’s U-test.
make any statement regarding the metabolism and tissue
distribution of the bepotastine besilate. However, the values
of concentration of bepotastine besilate between the serum
and the nasal mucosa were almost the same. Therefore,
we think that pathophysiologic changes are small in the
inferior turbinate accompanying CRS without AR. However,
we surmise that allergic conditions (edema, etc.) may cause
pathophysiologic changes in the nasal mucosa, because the
concentrationofbepotastinebesilateinthenasalmucosawas
lower in allergic conditions than in nonallergic conditions.
The values of concentration of bepotastine besilate both
in the serum and nasal mucosa were found to vary greatly.
Variations may result from variation of sampling time,
individualvariationofabsorption,metabolismandexcretion
of bepotastine besilate, and/or individual variation of its
pharmacokinetics in nasal mucosa. Also, it is necessary for
pharmacokinetics in the nasal mucosa to be sampled at least
two times.
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